Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by immune malfunction. Disease targets include patient populations with digestive disorders, such as exocrine pancreatic insufficiency in cystic fibrosis patients, and inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
IN THE NEWS
|
May 15, 2023
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
|
|
May 11, 2023
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
|
|
Apr 25, 2023
First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
|
